CFB
GMAB icon

Cullen/Frost Bankers’s Genmab GMAB Stock Holding History

Cullen/Frost Bankers’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.35K Sell
86
-9
-9% -$239 ﹤0.01% 1274
2026
Q1 		$2.55K Hold
95
– – ﹤0.01% 1236
2025
Q4 		$2.93K Buy
95
+20
+27% +$623 ﹤0.01% 1220
2025
Q3 		$2.3K Hold
75
– – ﹤0.01% 1215
2025
Q2 		$1.55K Sell
75
-513
-87% -$10.5K ﹤0.01% 1202
2025
Q1 		$11.5K Buy
588
+418
+246% +$8.77K ﹤0.01% 927
2024
Q4 		$3.55K Buy
170
+24
+16% +$527 ﹤0.01% 1063
2024
Q3 		$3.56K Buy
+146
New +$3.9K ﹤0.01% 1052
2023
Q2 		– Sell
-186
Closed -$7.02K – 1192
2023
Q1 		$7.02K Buy
+186
New +$7.15K ﹤0.01% 989

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cullen/Frost Bankers's GMAB Position: Q2 2026 in Review

Cullen/Frost Bankers reduced its Genmab (GMAB) stake by 9.5% in Q2 2026, selling an estimated $239 and leaving 86 shares worth $2.35K. The position accounts for ﹤0.01% of the portfolio, ranked #1274.

Cullen/Frost Bankers first reported a position in GMAB in Q1 2023 and has held it in 9 quarters since. The position peaked at $11.5K in Q1 2025. 290 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Cullen/Frost Bankers held 86 shares of Genmab worth $2.35K as of Q2 2026.
  • Cullen/Frost Bankers sold 9 Genmab shares in Q2 2026, an estimated $239.
  • Genmab made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q2 2026, its #1274 holding.
  • Cullen/Frost Bankers first reported a position in Genmab in Q1 2023 and has held it in 9 quarters since.
  • Cullen/Frost Bankers's Genmab position peaked at $11.5K in Q1 2025.
  • 290 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.